Potentia

Company Overview

Snapshot

Founded in April 2026, Potentia operates with 1–10 employees. The company has secured $90K across one funding round from one investor. In May 2026, Potentia received its first disclosed funding from Peregrine Ventures.

Business overview

Potentia Therapeutics is a biotechnology company focused on developing Antibody-Oligonucleotide Conjugates (AOCs) for targeted RNA therapies. Its core technology links short interfering RNA (siRNA) to target antibodies, enabling the direct delivery of RNA-interference therapeutics into peripheral nerve tissues to silence disease-causing genes. The company's platform addresses diseases of the Peripheral Nervous System (PNS), with its lead drug candidate targeting Charcot-Marie-Tooth disease 1A (CMT1A) to restore myelin formation and nerve function. Potentia also aims to extend its platform to other conditions, including diabetic peripheral neuropathy, chemotherapy-induced neuropathy, and age-related hearing loss, operating within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Biomaterials & Tissue Engineering.

Company Intelligence Q&A

When was Potentia founded?

Potentia was founded in April 2026.

What is Potentia's primary focus in biotechnology?

Potentia Therapeutics develops Antibody-Oligonucleotide Conjugates (AOCs) for targeted RNA therapies, specifically to treat diseases of the Peripheral Nervous System (PNS).

What is the company's lead drug candidate targeting?

Potentia's lead drug candidate targets Charcot-Marie-Tooth disease 1A (CMT1A) to restore myelin formation and nerve function.

What was Potentia's most recent funding event?

In May 2026, Potentia secured $90K in funding from Peregrine Ventures.

What other conditions does Potentia's platform aim to address?

Beyond CMT1A, Potentia's platform extends to other conditions including diabetic peripheral neuropathy, chemotherapy-induced neuropathy, and age-related hearing loss.